These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines. Yang J; Sontag D; Gong Y; Minuk GY Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415 [TBL] [Abstract][Full Text] [Related]
4. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105 [TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Massani M; Stecca T; Fabris L; Caratozzolo E; Ruffolo C; Furlanetto A; Morton S; Cadamuro M; Strazzabosco M; Bassi N Oncol Rep; 2013 Sep; 30(3):1143-8. PubMed ID: 23807641 [TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135 [TBL] [Abstract][Full Text] [Related]
7. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Liu R; Zhao R; Zhou X; Liang X; Campbell DJ; Zhang X; Zhang L; Shi R; Wang G; Pandak WM; Sirica AE; Hylemon PB; Zhou H Hepatology; 2014 Sep; 60(3):908-18. PubMed ID: 24700501 [TBL] [Abstract][Full Text] [Related]
8. Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways. Viereckl MJ; Krutsinger K; Apawu A; Gu J; Cardona B; Barratt D; Han Y Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740979 [TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Fingas CD; Mertens JC; Razumilava N; Sydor S; Bronk SF; Christensen JD; Ilyas SI; Canbay A; Treckmann JW; Paul A; Sirica AE; Gores GJ Hepatology; 2013 Oct; 58(4):1362-74. PubMed ID: 23703673 [TBL] [Abstract][Full Text] [Related]
10. Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma. Fu J; McGrath NA; Lee J; Wang X; Brar G; Xie C Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):485-492. PubMed ID: 35307294 [TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219 [TBL] [Abstract][Full Text] [Related]
13. Annexin A1: A new immunohistological marker of cholangiocarcinoma. Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846 [TBL] [Abstract][Full Text] [Related]
14. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885 [TBL] [Abstract][Full Text] [Related]
15. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979 [TBL] [Abstract][Full Text] [Related]
16. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b. Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763 [TBL] [Abstract][Full Text] [Related]
18. Circular RNAs in cholangiocarcinoma. Liao W; Feng Q; Liu H; Du J; Chen X; Zeng Y Cancer Lett; 2023 Jan; 553():215980. PubMed ID: 36336149 [TBL] [Abstract][Full Text] [Related]
19. γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus. Saengboonmee C; Sorin S; Sangkhamanon S; Chomphoo S; Indramanee S; Seubwai W; Thithuan K; Chiu CF; Okada S; Gingras MC; Wongkham S World J Gastroenterol; 2023 Jul; 29(28):4416-4432. PubMed ID: 37576707 [TBL] [Abstract][Full Text] [Related]
20. Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. Gentilini A; Lori G; Caligiuri A; Raggi C; Di Maira G; Pastore M; Piombanti B; Lottini T; Arcangeli A; Madiai S; Navari N; Banales JM; Di Matteo S; Alvaro D; Duwe L; Andersen JB; Tubita A; Tusa I; Di Tommaso L; Campani C; Rovida E; Marra F Hepatology; 2021 Oct; 74(4):2007-2020. PubMed ID: 33959996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]